Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.

Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear. The company's bispecific antibody, petosemtamab, showed promising results in a ...

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction ...

Shares of Merus N.V. MRUS rose 36.2% on Friday after management announced the publication of an abstract for the 2024 ASCO meeting on a mid-stage study evaluating the combination of its ...

Merus NV has seen a significant increase in market cap from $852mn to $3.46bn in the past year. Merus is a leader in developing multispecific antibodies with promising lead candidates petosemtamab and ...

Merus (NASDAQ:MRUS – Get Free Report) has been assigned an average recommendation of “Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat reports. Fourteen investment ...

We recently compiled a list of the Top 10 ADR Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other ADR stocks.

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other ...

(RTTNews) - Denmark's Genmab A/S (GMAB) has agreed to acquire Merus NV (MRUS), a Dutch biopharmaceutical company focused on treatments for head and neck cancer, in an all-cash transaction valued at ...